| Popis: |
The objective of the study was to develop optimized formulation of In-situ gel of Brimonidine tartarate (BT), anti-glaucoma agent using Ion activated polymer; Gelrite as gelling agent, kappa carrageenan as mucoadhesive agent and Hydroxy Propyl Methyl Cellulose (HPMC E50) as release retardant polymer. The 23 factorial design was employed to optimize the formulation considering concentration of Gelrite, kappa carrageenan and Hydroxy Propyl Methyl Cellulose as independent variables, mucoadhesive force (N). Viscosity (cP) and In-vitro percentage drug release as dependent variables. Based on mucoadhesive force (N), Viscosity(CPS) and In-vitro percentage drug release, formulation containing concentration Gelrite (0.39%), kappa carrageenan (0.21%) and HPMC E50 (0.4%) was found to be optimized formulation developed by23 factorial design. Formulation was prepared successfully and assessed for gelling capacity, pH, rheological studies,refractive index, optical clarity, isotonicity and as ocular irriation by hen’s egg chorioallantoic membrane (HET-CAM) Test. The overall results of this study revealed that the Brimonidine tartarate/kappa carrageenan in-situ system can be used to enhance ocular retention time. |
